Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 41.85M shares outstanding
USCarisma Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to pioneering chimeric antigen receptor (CAR) macrophage therapies specifically designed to target solid cancerous growths.
Its therapeutic approaches are instrumental in modulating both the inherent and acquired functions of the immune system.
The company's sophisticated platform draws upon breakthroughs in macrophage science, CAR design, and cell-based treatments to address various human ailments. Notably, Carisma Therapeutics maintains a key strategic alliance with Moderna Inc. Incorporated in 2016 and headquartered in Philadelphia, Pennsylvania, the organization was initially established as CARMA Therapeutics Inc., before rebranding to its current name, Carisma Therapeutics, Inc., in May of 2017.
Carrie L. Bourdow
Director
Glen MacDonald, Ph.D.
Chief Technology Officer
Jason A. Keyes
Director
Jay S. Duker, M.D.
Chair of the Board of Directors
Employees
46
Country
US
Sector
Healthcare
Website
carismatx.com
Loading congressional disclosures…
based on 41.85M shares outstanding
US30d Avg
3.13K
60d Avg
9.54K
90d Avg
9.72K
